Novartis
NEWS
Blackstone Life Sciences, a private investment firm, along with Novartis, launched Anthos Therapeutics with a $250 million investment. Anthos will be headquartered in Cambridge, Mass.
Months after Akcea Therapeutics unveiled positive mid-stage data that showed its therapy reduced elevated levels of lipoprotein(a) in patients with cardiovascular disease (CVD), Swiss pharma giant Novartis exercised its option to take license the therapy and take it through late-stage studies.
It’s nice to be admired. Fortune released its list of the most respected companies across the globe and one pharma company made the top 50 list.
On Monday, N.C. Gov. Roy Cooper announced the expansion to the company’s Durham facility that was first announced in May 2018. It’s expected to provide up to 200 additional jobs.
Novartis announced that the FDA approved the company’s Egaten to treat fascioliasis in patients six years of age and older. Novartis also inked a multi-target and multi-year collaboration with AbCellera.
There’s no doubt that drug prices, particularly sky-high prices for new biologics and companies jacking up the prices of older drugs, is a problem. And it’s definitely a political issue, especially now that candidates are declaring their plans to run for president in 2020.
Across parts of Europe, Asia and the rest of the globe, pharma and biotech companies have made strides and deals to advance their pipelines and technologies this week.
London-based Clinigen Group pc will now have full rights to Proleukin (aldesleukin, human recombinant interleukin-2). This morning, the U.K.-based pharmaceutical and services company struck a deal with Novartis to acquire the U.S. rights to the metastatic renal cell carcinoma treatment.
As Britain’s plans to leave the European Union—Brexit—stagger toward the March 29 deadline, the UK biopharma industry is taking stock of the likely impact.
JOBS
IN THE PRESS